• Home
  • Company
    • Management
    • Board of Directors
    • Advisory Board
  • Technology
    • Publications
  • Partnering
    • Product Pipeline
  • News
    • IN THE PRESS: Cloud Pharmaceuticals CSO Shahar Keinan in "The Scientist"
    • Cloud Pharmaceuticals to Present AI-Based Drug Design at Conferences in May
    • Cloud Pharmaceuticals Wins U.S.-China Health Summit
    • Cloud Pharmaceuticals Selected Finalist in U.S.-China Health Summit
    • Cloud Pharmaceuticals forms Drug Design Collaboration with GSK
    • Cloud Pharmaceuticals CEO to Speak at Artificial Intelligence in Drug Development Congress 27-28 September 2017, London, UK
    • Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation
    • Cloud Pharmaceuticals CEO to Speak at the AI in Pharma Summit October17, 2017 in Boston.
    • Cloud Pharmaceuticals CEO and CSO to Speak at AI Pharma Innovation
    • Undruggable? Not to Cloud Pharmaceuticals
    • Cloud Pharmaceuticals Announces Design of Active Pro-Drug for Treatment of Crohn's Disease and Ulcerative Colitis
    • Cloud Pharmaceuticals COO to Discuss Digital Tools for Drug Discovery and Development at the 2016 BIO International Convention
    • Cloud Pharmaceuticals Appoints Neurological Disorder Expert Jeff Vaught to Its Advisory Board
    • Cloud Pharmaceuticals Strengthens Management Team with Appointment of Two C-Level Executives
  • Events
  • Contact
Cloud Pharmaceuticals
Connect with us:

Technology

QMD. The company's drug discovery platform, Quantum Molecular Design ("QMD"), deploys an integrated combination of Artificial Intelligence, advanced quantum chemistry, and cloud computing to rapidly generate high quality drug-like hits and leads for a wide range of drug targets, including demonstrated success on targets previously considered to be "undruggable", at low cost.  The Artificial Intelligence methods used include augmented intelligence, heuristic search, expert systems and machine learning to reduce computational cost and reduce toxic side effects.  The company has achieved biological activity and promising preclinical data on 100% of the drug targets it has tested so far, including allosteric targets, protein-protein interaction disruption, nuclear receptors, and drug candidates designed for selectivity. 

​Quantum Computing.  In early 2020, Cloud Pharmaceuticals completed a collaboration with Fujitsu where it developed substantial new intellectual property surrounding how to discover new drugs rapidly using a variation of its QMD technology running on a quantum computing emulator.  The collaboration lead to a body of original IPO that Cloud uniquely owns for using quantum computing to design new drugs in a matter of minutes.  Cloud is now in the process of transferring this IP to a spinout venture called PolarisQB, a new company whose mission is to speed up molecular design.  Cloud expects to launch 10 new drug discovery and development programs using this method.

Polypharmacy Drug Design.  Cloud Pharmaceuticals has also developed a new method to use AI and complex systems simulation to design "polypharmacy" therapeutics based on modulating biological circuits rather than inhibiting proteins.  Cloud believes this new method will rival targeted therapeutics as a dominant new way to design, develop and deliver therapies for disease.  Polypharmacy refers to bundling several drugs, old and new, into a time stages delivery that has the effect of controlling network pathways.  Cloud expects this new development to remain a major research project for the next 2-3 years under a new R&D staff who will operate separately from the drug development operation of Cloud.

Collaborative Hit Database for the Druggable Genome.  In partnership with NC State University and several other biotech research organizations, Cloud is participating in a project to build and offer a database of a large number of novel hits to the entire druggable genome as an open source research project for pre-competitive collaboration that will enable the industry to skip many early time consuming stages of discovery for inhibiting, drugging or modulating biological proteins and pathways.  the first release of this collaborative effort is expected by the end of the year.

AI at Every Stage of Drug Development.  Cloud is partnering with multiple R&D organizations to leverage data and AI at every stage of the drug development process, from preclinical, to pipeline management, to clinical stage development.  Our partners include, but are not limited to NC State University, Mercury Data Science and Nashville Biosciences.


PREVIOUS PUBLICATIONS: 
​
“Leveraging cloud computing for In-Silico drug design”
Keinan, S.; Hatcher-Frush, E.; and Shipman, W. J.; IEEE Trans. Comp. Sci. Eng. 10 July 2018

https://ieeexplore.ieee.org/abstract/document/8409367/​

"An Effective Way to Apply AI to the Design of New Drug Lead Compounds"
 Keinan, S.; Shipman, W. J.; and Addison, E.; Pharma IQ Clin. Disc. & Dev. (2019) June 11.
https://www.pharma-iq.com/pre-clinical-discovery-and-development/articles/an-effective-way-to-apply-ai-to-the-design-of-new-drug-lead-compounds

Please also see the Publications page for a longer list.
HOME | COMPANY | TECHNOLOGY | PARTNERING | NEWS | EVENTS | CONTACT

CONTACT US:

Cloud Pharmaceuticals, Inc.

Office: 800 Park Offices Dr., RTP, NC 27709
Mail: PO Box 110081, RTP, NC 27709
Phone: 1.910.398.1200
e-mail: info@cloudpharmaceuticals.com
CONNECT WITH US:


SUBSCRIBE:

Join our contact list to receive news and announcements in your inbox:

Join Now
© 2014 - 2019 Cloud Pharmaceuticals, Inc. | Terms and Conditions of access to www.cloudpharmaceuticals.com